Results 241 to 250 of about 4,456,677 (340)

The subcellular distribution of phosphorylated Y‐box‐binding protein‐1 at S102 in colorectal cancer patients, stratified by KRAS mutational status and clinicopathological features

Molecular Oncology, EarlyView.
This study identifies nuclear YB‐1 S102 phosphorylation as a marker associated with KRAS and FBXW7 mutations in colorectal cancer. Mutated KRAS correlates specifically with nuclear, not cytoplasmic, S102 YB‐1. These findings provide the first ex vivo evidence of this link in CRC and suggest future studies should assess the prognostic and therapeutic ...
Konstanze Lettau, Stephan Forchhammer, Birgit Fehrenbacher, Lejla Mahmutovic, Marcus Scharpf, Gunnar Blumenstock, Martin Schaller, Irina Bonzheim, Shayan Khozooei, Mahmoud Toulany   +9 more
wiley   +1 more source

A new method of graduating glass beads, for the purpose of ascertaining the specific gravities of fluids [PDF]

W. Ferguson
openalex   +1 more source

On the Survival of Specific Microorganisms in Pupae and Imagines of Musca Domestica raised from experimentally Infected Larvae. Experiments with B. Typhosus [PDF]

, 1911
J. C. G. Ledingham
openalex   +1 more source

Specificities of lipases

Journal of Lipid Research, 1963
P. Savary, P. Desnuelle
openaire   +4 more sources

T-cell Receptor Profiling of Blood to Detect Lung Cancer. [PDF]

Cancer Immunol Res
Søgaard MT, Tseng D, Gibbs S, Wu W, Nolan LG, Yang PY, Lai M, Cao J, Pipavath S, Mayer-Blackwell K, Newell EW, Houghton AM, Payne KK, Chiou SH, Nair VS.   +14 more
europepmc   +1 more source

A nucleotide‐independent, pan‐RAS‐targeted DARPin elicits anti‐tumor activity in a multimodal manner

Molecular Oncology, EarlyView.
We report a Designed Ankyrin Repeat Protein that binds and inhibits RAS proteins, which serve as central cell signaling hubs and are essential for the progression of many cancers. Its unique feature is that it does not discriminate between different RAS isoforms or mutations and is capable of binding to RAS in both its active (GTP‐bound) and inactive ...
Jonas N. Kapp, Wouter P. R. Verdurmen, Jonas V. Schaefer, Kari Kopra, Gabriela Nagy‐Davidescu, Elodie Richard, Marie‐Julie Nokin, Patrick Ernst, Rastislav Tamaskovic, Martin Schwill, Ralph Degen, Claudia Scholl, David Santamaria, Andreas Plückthun   +13 more
wiley   +1 more source

LXIX. Remarks on Sir David Brewster's paper “On the absorption of specific rays”. In a Letter to Sir David Brewster, K.H. LL.D. F.R.S. [PDF]

George Biddell Airy
openalex   +1 more source

Evaluation of Six Commercial and Noncommercial Colistin Resistance Diagnostics. [PDF]

Microbiologyopen
Leshaba TMS, Mmatli M, Mbelle NM, Osei Sekyere J.   +3 more
europepmc   +1 more source

Therapeutic applications of a novel humanized monoclonal antibody targeting chemokine receptor CCR9 in pancreatic cancer

Molecular Oncology, EarlyView.
C–C chemokine receptor type 9 (CCR9) is an immune checkpoint in pancreatic ductal adenocarcinoma (PDAC). Novel anti‐CCR9 antibody SRB2 was evaluated in combination with cytotoxic chemotherapy in PDAC cells, patient‐derived organoids, patient‐derived xenografts, and humanized mouse models.
Hannah G. McDonald, Anna M. Reagan, Charles J. Bailey, Mei Gao, Muqiang Gao, Angelica L. Solomon, Michael J. Cavnar, Prakash K. Pandalai, Mautin T. Barry‐Hundeyin, Megan M. Harper, Justin A. Rueckert, Ángela Turrero, Araceli Tobio, Anxo Vidal, Daniel Roca‐Lema, Elia Álvarez‐Coiradas, Pablo Garrido, Laureano Simón, Joseph Kim   +18 more
wiley   +1 more source

ON THE SPECIFIC IDENTITY OF VIVIPARA DILUVIANA, KUNTH, AND VIVIPARA CLACTONENSIS, S. V. WOOD

, 1904
A. S. Kennard, B. B. Woodward
openalex   +2 more sources